MONTREAL, Jan. 14 /CNW Telbec/ - Arura Pharma Inc. (TSXV: ARP) ("Arura")
is pleased to announce record sales results for the 3 months and the 12 months
periods ended December 31, 2007. The unaudited numbers for the 4th quarter of
2007 showed record sales compared to the 3rd quarter of the same year, which
was also a record quarter and compared to the same quarter in 2006 and
compared to the whole fiscal year ended on December 31, 2006.
(*)Arura recorded sales of $4,657,000 for the 4th quarter of 2007.
This is an increase of:
- 61% over the 3rd quarter of 2007;
- 182% over the 4th quarter of 2006.
(*)Arura recorded sales of $10,106,000 for the fiscal year 2007.
This is an increase of:
- 103% over 2006;
- 194% over 2005.
"We are particularly proud of our sales for the fiscal year 2007 which
largely surpass our initially budgeted sales for that year" said Ali
Moghaddam, President and CEO. Pierre Fortin, COO of Arura, added "These record
sales on a quarterly and an annual basis evidence the success of the
integration of our previous transactions and the capacity of Arura's
management to grow its business in an highly competitive environment both from
an organic and an M&A standpoint". "We are confident that these strong results
will soon be reflected in Arura stock price and will widen the spectrum of
financing and acquisition opportunities for Arura" concluded Daniel Pharand,
Chairman of Arura.
About Arura Pharma Inc.
Arura is a specialty pharmaceutical company consisting of two business
units, namely an established consumer health business unit manufacturing and
distributing beauty and personal hygiene products in Canada and in the United
States and an emerging specialty pharmaceutical business unit geared at
acquiring and commercializing established prescription drugs and medical
devices in the oncology, wound care and neurology sectors, amongst others.
The TSX Venture Exchange has not reviewed and does not accept
responsibility for the adequacy or accuracy of this press release.
Cautionary Statement on Forward-Looking Information:
This release contains certain "forward-looking statements" including,
without limitation, expectations, beliefs, plans and objectives regarding the
potential transactions and ventures discussed in this release. Among the
important factors that could cause actual results to differ materially from
those indicated by such forward-looking statements are the risks inherent in
pharmaceutical manufacturing and distribution, the need to obtain additional
financing, the availability of needed personnel and fluctuations in general
For further information:
For further information: Daniel Pharand, Chairman, Arura Pharma Inc.,
(514) 984-4431, email@example.com; Ali Moghaddam, Chief Executive Officer,
Arura Pharma Inc., (450) 442-2545 ext. 233, firstname.lastname@example.org